Why Guardant Health, Inc. (GH) Stock Rose 5.3% on Oct 5, 2026
What happened
Guardant Health rose 3.30% to $183.67 after the company announced publication of positive COSMOS-MEL01 study results in *Cancer Research Communications*, demonstrating the tissue-free Guardant Reveal blood test's ability to detect molecular residual disease in stage II–III melanoma patients (web_catalyst via MarketWatch and Yahoo Finance). This marks the first prospective, multicenter evaluation of this application. Volume was below average at 0.58x expected for this point in the session.
Guardant Health earnings scheduled for 2026-10-28 (consensus EPS estimate: −$0.75); monitor for guidance updates on COSMOS-MEL01 commercialization timelines and insurance reimbursement progress.
Other developments that session
Guardant Health's COSMOS study validating Guardant Reveal liquid biopsy for melanoma recurrence prediction published in Cancer Research Communications.
Reviewing Guardant Health (NASDAQ:GH) & Privia Health Group (NASDAQ:PRVA)
Frequently asked questions
Why did Guardant Health, Inc. (GH) stock rise on Oct 5, 2026?
Guardant Health rose 3.30% to $183.67 after the company announced publication of positive COSMOS-MEL01 study results in *Cancer Research Communications*, demonstrating the tissue-free Guardant Reveal blood test's ability to detect molecular residual disease in stage II–III melanoma patients (web_catalyst via MarketWatch and Yahoo Finance). This marks the first prospective, multicenter evaluation of this application. Volume was below average at 0.58x expected for this point in the session.
How much did GH stock rise on Oct 5, 2026?
GH rose 5.3% during the Oct 5, 2026 trading session.